Author bio: Guest
post is submitted by Sasha Bakhru, the VP, CTO
and Co-founder of Perosphere Inc. Go to
his website for more information.
Persophere Inc. is attracting a significant amount of
attention in the biomedicine and pharmaceuticals industry. Persophere Inc. is a specialty
pharmaceuticals company that is attempting to make a huge impact on these
crucial developing fields.
Perosphere is the brain-child of multiple leading scientists
and researchers. One of the important
players behind this genius organization is Sasha Bakhru, a leading scientist and medical researcher. Bakhru serves multiples functions for this
important organization. He was one of
the co-founders. He also works there as
the Vice President and the Chief Technology Officer.
Perosphere Inc. is working to make significant changes and
developments to the pharmaceuticals industry.
Currently, they are working to innovate and update drug designs as well
as drug delivery technology. They are
working to develop and change “rescue” drugs.
They currently have patents on many important products and
technology. They also have various pending
patents on their versatile and innovative products. Perosphere is tremendously
discerning when it comes to the kinds of chemicals and therapeutics that they
use in their products. They only utilize
the highest quality chemicals around.
When Bakhru isn’t working at
Perosphere, he’s busy working as an Adjunct Assistant Professor of Medical
Science at Brown University. He has also
completed a Postdoctoral Fellowship with Dr. Mathiowitz at Brown
University. Bakhru has always been
passionate about his educational pursuits.
Not only as he completed his B.S. in Biomedical Engineering from
Columbia University, he also earned his M.S.E from John Hopkins University in
Materials Science and a Ph.D. from Carnegie Mellon University in Biomedical
Engineering.
With leaders
like Bakhru running Perosphere, this pharmaceuticals company will undoubtedly
accomplish their goal to change the way that drugs are delivered and
distributed forever.
No comments:
Post a Comment